Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623746 | 0.93 | HSD17B10 (0.41) | ACKR3CHRM3NOTUMLCKL3MBTL1 | |
| SCHEMBL1623373 | 0.87 | EPHX2 (0.42) | CHRM4PTGESTP53CHRM2LMNA | |
| SCHEMBL1624860 | 0.86 | POLB (0.42) | CHRM4PTGESTP53NOTUMLMNA | |
| SCHEMBL1625064 | 0.83 | TP53 (0.41) | CHRM3TP53NOTUMLMNAMEN1 | |
| SCHEMBL1625656 | 0.81 | HSD17B10 (0.41) | NOTUM | |
| SCHEMBL1625651 | 0.81 | HSD17B10 (0.41) | NOTUM | |
| SCHEMBL1624933 | 0.80 | CHRM2 (0.42) | CHRM4CHRM2LMNAMEN1KMT2A | |
| SCHEMBL1284034 | 0.80 | PDE3B (0.46) | PTGESTP53NOTUMPDE3BPDE3A | |
| SCHEMBL1625450 | 0.79 | ALDH1A1 (0.46) | PTGESTP53LMNA | |
| Hydrochloric Acid SCHEMBL1284592 | 0.79 | PDE3B (0.46) | PTGESTP53NOTUMPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | ACKR3 568/4885CHRM3 4166/4885CHRM4 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.